APOLLOHOSP Share Price, Analysis & Fundamentals

Strong YoY revenue and profit growth are underpinned by a bullish technical trend, though the stock trades near its 52-week high with limited volume conviction.

The stock is exhibiting a strong bullish technical trend, supported by its price trading above key moving averages (9, 21, and 50-day EMAs) and a positive trend alignment score of 3. This suggests a healthy uptrend is in place, with momentum indicated by an RSI of 61.83, placing it in the 74.79th percentile over the past year, implying continued upward potential.
Fundamental performance for the Mar 2026 quarter was robust, with revenue increasing by 18.133% year-over-year to ₹6,606 Cr and net profit surging by 33.092% year-over-year to ₹551 Cr. Earnings per share (EPS) also saw a significant 35.83% YoY jump to ₹36.81, indicating strong operational efficiency and profitability growth.
Analyst sentiment remains overwhelmingly positive, with 84.6% of ratings being 'Strong Buy' or 'Buy', and this distribution has been stable over the past month. This consensus suggests that market experts see continued upside potential for the stock.
Institutional investors, including FIIs and DIIs, collectively hold a substantial 65.38% of the company's shares as of Mar 2026. While FIIs decreased their stake slightly by 0.92% last quarter, DIIs increased theirs by 1.26%, indicating a subtle shift in institutional preference within the broader holdings.
Upcoming events include a crucial meeting of secured creditors on June 24, 2026, to approve Apollo's composite scheme of arrangement, which could significantly impact the company's structure and future operations. Additionally, a key management change was announced with the resignation of Mr. Dinesh Madhavan as President - Group Oncology and International, effective May 30, 2026.

The stock has shown positive short-term returns, with a 1-month return of 7.08% and a 3-month return of 6.25%.
The trend is currently bullish, with the price trading above the 9, 21, and 50-day EMAs, and the trend alignment score is 3.
Momentum is strong, indicated by an RSI of 61.83, placing it in the 74.79th percentile over the past year.
Volatility is moderate, with the price positioned at 76.75% of the Bollinger Band width, and an annualized volatility of 20.68%.
The stock is trading 1.24% below its 52-week high and has experienced a current drawdown of -1.24%.

The stock exhibits a bullish technical setup, characterized by positive short-term returns and a strong uptrend supported by EMAs. Momentum indicators like RSI are in favorable territory, suggesting continued upward potential. While volatility is present, the price remains within a healthy range relative to Bollinger Bands and its 52-week structure. Volume trends do not show significant conviction at this moment, but the overall technical picture remains positive.

Revenue for Mar 2026 quarter was ₹6,606 Cr, a 1.992% increase QoQ and an 18.133% increase YoY.
Net profit for Mar 2026 quarter was ₹551 Cr, showing a 6.783% increase QoQ and a significant 33.092% increase YoY.
EPS for Mar 2026 quarter was ₹36.81, up 5.382% QoQ and 35.83% YoY.
Profit before tax saw a 5.865% QoQ and 39.922% YoY increase, reaching ₹722 Cr in Mar 2026 quarter.

A meeting of secured creditors is scheduled for June 24, 2026, to approve Apollo's composite scheme of arrangement. Separately, Mr. Dinesh Madhavan has resigned as President - Group Oncology and International, effective May 30, 2026.